Next Article in Journal
Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer
Next Article in Special Issue
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
Previous Article in Journal
Stabilization of Nucleosomes by Histone Tails and by FACT Revealed by spFRET Microscopy
Previous Article in Special Issue
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Cancers 2017, 9(1), 4; doi:10.3390/cancers9010004

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer

1
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
2
Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Emmanuel S. Antonarakis
Received: 10 November 2016 / Revised: 2 January 2017 / Accepted: 4 January 2017 / Published: 6 January 2017
(This article belongs to the Special Issue AR Signaling in Human Malignancies: Prostate Cancer and Beyond)
View Full-Text   |   Download PDF [760 KB, uploaded 6 January 2017]   |  

Abstract

Background: Triple-negative breast cancer (TNBC) has a poor prognosis because of frequent recurrence. Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is not clearly defined. The aim of this study was to explore the expression of AR and its relationship with clinicopathologic features in TNBC. Methods: This study investigated 1036 cases of sporadic invasive breast carcinoma. Immunohistochemical assays were performed to determine the expression of AR in 190 TNBC samples. The relationships between AR expression and clinicopathologic data and prognosis were analyzed. Results: In 190 TNBC cases, the prognosis of AR-positive patients was significantly better (p = 0.019, log-rank) than AR-negative patients, and in multivariate analysis, AR expression was an independent indicator of good prognosis (p = 0.039, hazard ratio = 0.36). In patients with disease relapse, AR positivity was significantly correlated with better prognosis (p = 0.034, log-rank). Conclusions: AR expression may be useful as a subclassification marker for prognosis in TNBC. View Full-Text
Keywords: triple-negative breast cancer; androgen receptor; prognostic marker; individualized treatment; intrinsic subtype triple-negative breast cancer; androgen receptor; prognostic marker; individualized treatment; intrinsic subtype
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Asano, Y.; Kashiwagi, S.; Goto, W.; Tanaka, S.; Morisaki, T.; Takashima, T.; Noda, S.; Onoda, N.; Ohsawa, M.; Hirakawa, K.; Ohira, M. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. Cancers 2017, 9, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top